AAPL325.13+8.28 (+2.61%) ▲|ABBV259.99+3.57 (+1.39%) ▲|ABT109.01-1.35 (-1.22%) ▼|ACN187.78-1.98 (-1.04%) ▼|ADBE286.13-6.66 (-2.27%) ▼|AMAT441.46-16.93 (-3.69%) ▼|AMD458.55-12.18 (-2.59%) ▼|AMGN436.55+6.67 (+1.55%) ▲|AMT175.22-0.48 (-0.27%) ▼|AMZN254.36-5.41 (-2.08%) ▼|AVGO369.85-0.49 (-0.13%) ▼|AXP324.87-5.30 (-1.61%) ▼|BA205.97-1.82 (-0.87%) ▼|BAC62.01+0.07 (+0.10%) ▲|BKNG196.38-2.71 (-1.36%) ▼|BLK1,132.28-23.33 (-2.02%) ▼|BMY66.79-0.03 (-0.04%) ▼|BNY160.30-0.98 (-0.61%) ▼|BRK-B502.70-1.34 (-0.26%) ▼|C132.61+0.99 (+0.75%) ▲|CAT778.76-18.71 (-2.35%) ▼|CL89.82-0.01 (-0.01%) ▼|CMCSA26.33-0.30 (-1.11%) ▼|COF211.23-3.28 (-1.53%) ▼|COP135.82+3.33 (+2.51%) ▲|COST936.41-7.48 (-0.79%) ▼|CRM258.02+0.48 (+0.19%) ▲|CSCO109.59-0.90 (-0.81%) ▼|CVS96.70+2.79 (+2.97%) ▲|CVX210.30+4.16 (+2.02%) ▲|DE673.95+19.04 (+2.91%) ▲|DHR207.18-6.38 (-2.99%) ▼|DIS106.39-1.16 (-1.08%) ▼|DUK120.14+0.23 (+0.19%) ▲|EMR147.64-4.80 (-3.15%) ▼|FDX322.27-5.14 (-1.57%) ▼|GD369.56-1.79 (-0.48%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV896.11-2.42 (-0.27%) ▼|GILD149.03+2.69 (+1.83%) ▲|GM85.59-0.74 (-0.85%) ▼|GOOG331.48-3.93 (-1.17%) ▼|GOOGL334.61-4.74 (-1.40%) ▼|GS1,005.29-15.61 (-1.53%) ▼|HD319.07-8.76 (-2.67%) ▼|HON209.85-3.68 (-1.72%) ▼|IBM230.26-3.62 (-1.55%) ▼|INTC88.57-0.94 (-1.05%) ▼|INTU344.30-15.00 (-4.17%) ▼|ISRG367.60-9.27 (-2.46%) ▼|JNJ270.73+4.88 (+1.84%) ▲|JPM355.67-0.35 (-0.10%) ▼|KO88.02-0.65 (-0.73%) ▼|LIN486.14-3.44 (-0.70%) ▼|LLY1,158.16+1.43 (+0.12%) ▲|LMT542.26-15.53 (-2.78%) ▼|LOW199.52-5.18 (-2.53%) ▼|LRCX289.06-12.43 (-4.12%) ▼|MA583.23-6.08 (-1.03%) ▼|MCD261.59-0.09 (-0.03%) ▼|MDLZ61.48-0.59 (-0.95%) ▼|MDT91.91+1.26 (+1.39%) ▲|META579.87+7.53 (+1.32%) ▲|MMM170.62-1.21 (-0.70%) ▼|MO69.91+1.43 (+2.09%) ▲|MRK149.87+2.11 (+1.43%) ▲|MS211.78-1.55 (-0.72%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU930.78-27.95 (-2.92%) ▼|NEE82.57+0.23 (+0.28%) ▲|NFLX80.85-0.20 (-0.25%) ▼|NKE38.08-0.57 (-1.47%) ▼|NOW143.83-4.16 (-2.81%) ▼|NVDA217.62-2.88 (-1.31%) ▼|ORCL141.13-7.99 (-5.36%) ▼|PEP139.52-0.82 (-0.58%) ▼|PFE28.51+0.05 (+0.18%) ▲|PG146.39+1.27 (+0.88%) ▲|PLTR181.92-4.46 (-2.39%) ▼|PM188.48+1.18 (+0.63%) ▲|QCOM166.67-3.81 (-2.23%) ▼|RTX204.39-3.34 (-1.61%) ▼|SBUX105.66-0.60 (-0.56%) ▼|SCHW108.02-1.80 (-1.64%) ▼|SO88.11+0.11 (+0.12%) ▲|SPG211.67-0.65 (-0.31%) ▼|T26.13+0.24 (+0.93%) ▲|TMO601.80-15.30 (-2.48%) ▼|TMUS182.35+1.91 (+1.06%) ▲|TSLA356.16-11.80 (-3.21%) ▼|TXN253.08-7.83 (-3.00%) ▼|UBER75.22-0.43 (-0.57%) ▼|UNH395.79+6.38 (+1.64%) ▲|UNP288.95-11.72 (-3.90%) ▼|UPS102.51-1.72 (-1.65%) ▼|USB61.02-0.56 (-0.91%) ▼|V373.55-5.83 (-1.54%) ▼|VZ50.43+0.41 (+0.81%) ▲|WFC86.65+0.26 (+0.30%) ▲|WMT105.91+1.04 (+0.99%) ▲|XOM164.33+3.38 (+2.10%) ▲|AAPL325.13+8.28 (+2.61%) ▲|ABBV259.99+3.57 (+1.39%) ▲|ABT109.01-1.35 (-1.22%) ▼|ACN187.78-1.98 (-1.04%) ▼|ADBE286.13-6.66 (-2.27%) ▼|AMAT441.46-16.93 (-3.69%) ▼|AMD458.55-12.18 (-2.59%) ▼|AMGN436.55+6.67 (+1.55%) ▲|AMT175.22-0.48 (-0.27%) ▼|AMZN254.36-5.41 (-2.08%) ▼|AVGO369.85-0.49 (-0.13%) ▼|AXP324.87-5.30 (-1.61%) ▼|BA205.97-1.82 (-0.87%) ▼|BAC62.01+0.07 (+0.10%) ▲|BKNG196.38-2.71 (-1.36%) ▼|BLK1,132.28-23.33 (-2.02%) ▼|BMY66.79-0.03 (-0.04%) ▼|BNY160.30-0.98 (-0.61%) ▼|BRK-B502.70-1.34 (-0.26%) ▼|C132.61+0.99 (+0.75%) ▲|CAT778.76-18.71 (-2.35%) ▼|CL89.82-0.01 (-0.01%) ▼|CMCSA26.33-0.30 (-1.11%) ▼|COF211.23-3.28 (-1.53%) ▼|COP135.82+3.33 (+2.51%) ▲|COST936.41-7.48 (-0.79%) ▼|CRM258.02+0.48 (+0.19%) ▲|CSCO109.59-0.90 (-0.81%) ▼|CVS96.70+2.79 (+2.97%) ▲|CVX210.30+4.16 (+2.02%) ▲|DE673.95+19.04 (+2.91%) ▲|DHR207.18-6.38 (-2.99%) ▼|DIS106.39-1.16 (-1.08%) ▼|DUK120.14+0.23 (+0.19%) ▲|EMR147.64-4.80 (-3.15%) ▼|FDX322.27-5.14 (-1.57%) ▼|GD369.56-1.79 (-0.48%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV896.11-2.42 (-0.27%) ▼|GILD149.03+2.69 (+1.83%) ▲|GM85.59-0.74 (-0.85%) ▼|GOOG331.48-3.93 (-1.17%) ▼|GOOGL334.61-4.74 (-1.40%) ▼|GS1,005.29-15.61 (-1.53%) ▼|HD319.07-8.76 (-2.67%) ▼|HON209.85-3.68 (-1.72%) ▼|IBM230.26-3.62 (-1.55%) ▼|INTC88.57-0.94 (-1.05%) ▼|INTU344.30-15.00 (-4.17%) ▼|ISRG367.60-9.27 (-2.46%) ▼|JNJ270.73+4.88 (+1.84%) ▲|JPM355.67-0.35 (-0.10%) ▼|KO88.02-0.65 (-0.73%) ▼|LIN486.14-3.44 (-0.70%) ▼|LLY1,158.16+1.43 (+0.12%) ▲|LMT542.26-15.53 (-2.78%) ▼|LOW199.52-5.18 (-2.53%) ▼|LRCX289.06-12.43 (-4.12%) ▼|MA583.23-6.08 (-1.03%) ▼|MCD261.59-0.09 (-0.03%) ▼|MDLZ61.48-0.59 (-0.95%) ▼|MDT91.91+1.26 (+1.39%) ▲|META579.87+7.53 (+1.32%) ▲|MMM170.62-1.21 (-0.70%) ▼|MO69.91+1.43 (+2.09%) ▲|MRK149.87+2.11 (+1.43%) ▲|MS211.78-1.55 (-0.72%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU930.78-27.95 (-2.92%) ▼|NEE82.57+0.23 (+0.28%) ▲|NFLX80.85-0.20 (-0.25%) ▼|NKE38.08-0.57 (-1.47%) ▼|NOW143.83-4.16 (-2.81%) ▼|NVDA217.62-2.88 (-1.31%) ▼|ORCL141.13-7.99 (-5.36%) ▼|PEP139.52-0.82 (-0.58%) ▼|PFE28.51+0.05 (+0.18%) ▲|PG146.39+1.27 (+0.88%) ▲|PLTR181.92-4.46 (-2.39%) ▼|PM188.48+1.18 (+0.63%) ▲|QCOM166.67-3.81 (-2.23%) ▼|RTX204.39-3.34 (-1.61%) ▼|SBUX105.66-0.60 (-0.56%) ▼|SCHW108.02-1.80 (-1.64%) ▼|SO88.11+0.11 (+0.12%) ▲|SPG211.67-0.65 (-0.31%) ▼|T26.13+0.24 (+0.93%) ▲|TMO601.80-15.30 (-2.48%) ▼|TMUS182.35+1.91 (+1.06%) ▲|TSLA356.16-11.80 (-3.21%) ▼|TXN253.08-7.83 (-3.00%) ▼|UBER75.22-0.43 (-0.57%) ▼|UNH395.79+6.38 (+1.64%) ▲|UNP288.95-11.72 (-3.90%) ▼|UPS102.51-1.72 (-1.65%) ▼|USB61.02-0.56 (-0.91%) ▼|V373.55-5.83 (-1.54%) ▼|VZ50.43+0.41 (+0.81%) ▲|WFC86.65+0.26 (+0.30%) ▲|WMT105.91+1.04 (+0.99%) ▲|XOM164.33+3.38 (+2.10%) ▲|
26.9 C
New York
Tuesday, September 1, 2026

Tag: therapy

newssourceFORcompanyinformationcontent1releasesmarket

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney diseaseZHUBEI CITY, Taiwan and RALEIGH, N.C.,...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

Press release – No. 13 / 2026 

Avaana Launches National Registration Readiness Program to Help Disability Providers Meet New Mandatory NDIS Compliance Requirements

New end-to-end compliance initiative supports providers preparing for the Federal Government’s expanded NDIS registration reforms ahead of the July 2027 Mandatory Registration deadline

St. Joseph’s Children’s Hospital Cancer Survivor Advocates for Children’s Health Care on Capitol Hill

TAMPA, Fla., June 5, 2026 /PRNewswire/ -- This week, 7-year-old Mikey Hartnett and his parents joined leaders from BayCare and St. Joseph's Children's Hospital...

In HelloNation, Expert Corporate Wellness Strategist Valarie L. Harris, LPC-MHSP-S, NCC, Highlights the Importance of Pattern Recognition

CLARKSVILLE, Tenn., June 5, 2026 /PRNewswire/ -- What leadership skills are most essential for building healthy and effective teams? In a HelloNation article, Expert...

Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients...

PRESS RELEASE 

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers